EUVIMEDOpdag EUVIMED
Crossref

Prevention of medication‐related osteonecrosis of the jaw: institutional insights from a retrospective study

Y S Chang iD, S Nanayakkara iD, A Yaacoub, S C Cox

Australian Dental Journal · 2025

DOI: 10.1111/adj.13050 ↗

At a glance

Journal article in Australian Dental Journal, 2025. Written by Y S Chang and 3 co-authors. Institution: The School of Dentistry, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. Major MEDLINE topics: Bisphosphonate-Associated Osteonecrosis of the Jaw, Tooth Extraction. Cited 11 times so far (Crossref); 42 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Medication‐related osteonecrosis of the jaw (MRONJ) is a serious, debilitating condition of the jaw bones. Dental extraction is the most significant independent risk factor for MRONJ. This interim study aimed to evaluate the demographics, medical data and outcomes of patients at risk for MRONJ who underwent dental extractions in a dedicated MRONJ clinic following a risk reduction protocol at a large public dental clinic in New South Wales Health.

Methods

A retrospective study analysed demographic and clinical data of patients at risk for MRONJ who underwent dental extractions between March 2020 and April 2024.

Results

Data from 329 at‐risk patients who underwent 836 dental extractions were included. Most patients were women (75.1%) with a median age of 74 years (IQR 67–80). The primary indication for medications was osteoporosis (85.4%), with Denosumab being the most frequently prescribed (66.9%). Eighteen patients (5.5%) developed MRONJ at 8 weeks of follow‐up. Patients categorized as high‐risk had a higher incidence of MRONJ (72.2%) compared to the low‐risk group (22.2%).

Conclusion

This study is the first retrospective audit carried out after implementing preventive protocols in this dedicated MRONJ clinic. The higher incidence of MRONJ in patients classified as ‘high risk’ underscores the importance of considering individual risk factors in their treatment.

Subjects

MeSH terms (MEDLINE)

Bisphosphonate-Associated Osteonecrosis of the JawTooth ExtractionHumansRetrospective StudiesFemaleAgedMaleAged, 80 and overRisk FactorsBone Density Conservation AgentsDenosumabOsteoporosisNew South WalesMiddle AgedIncidence

Author keywords

MRONJosteonecrosispreventiontooth extraction

Substances

Bone Density Conservation AgentsDenosumab

Authors and institutions

  • The School of Dentistry, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Nepean Centre for Oral Health, Nepean Hospital, NBMLHD Kingswood, Penrith, New South Wales, Australia.

ORCID profiles: Y S Chang, S Nanayakkara

Cite

APA

Chang, Y. S., Nanayakkara, S., Yaacoub, A., & Cox, S. C. (2025). Prevention of medication‐related osteonecrosis of the jaw: institutional insights from a retrospective study. Australian Dental Journal. https://doi.org/10.1111/adj.13050

Vancouver

Chang YS, Nanayakkara S, Yaacoub A, Cox SC. Prevention of medication‐related osteonecrosis of the jaw: institutional insights from a retrospective study. Australian Dental Journal. 2025. doi:10.1111/adj.13050

BibTeX
@article{Chang2025,
  author = {Chang, Y S and Nanayakkara, S and Yaacoub, A and Cox, S C},
  title = {Prevention of medication‐related osteonecrosis of the jaw: institutional insights from a retrospective study},
  journal = {Australian Dental Journal},
  year = {2025},
  doi = {10.1111/adj.13050}
}
Start for free →